Cybersecurity in Pharmaceutical Manufacturing: OT, GMP and Converging FDA Regulations

OT in Pharma: Production and Validation Systems

Pharmaceutical manufacturing is one of the sectors where the convergence of quality, operational safety and cybersecurity is most acute. The OT systems found in a pharmaceutical plant do not merely control production processes: they manage parameters critical to the quality of the final product and to regulatory compliance.

SCADA for fermentation control, environmental monitoring systems in cleanrooms, autoclaves and sterilization systems controlled by PLCs, HVAC plants with precise temperature and humidity control, purified water and WFI (Water For Injection) management systems: every component of this ecosystem is a computerized system subject to validation, and every validated system is potentially exposed to the same cyber risks as any other OT system.

The difference compared with other industrial sectors is that a compromise here is not limited to an operational impact: it can compromise the integrity of batch data, make entire production batches non-compliant, and in the worst cases put the safety of the end patient at risk.

FDA 21 CFR Part 11 and Annex 11: The Starting Point

FDA 21 CFR Part 11 and its European equivalent, Annex 11 of the EMA's GMP, have regulated computerized systems in pharma since before cybersecurity became a mainstream concern. They cover audit trails, access control, electronic signatures, backup and system validation.

Many of the requirements in these standards anticipate information security concepts: the tamper-proof audit trail is a security log, role-based access control is identity governance, and system validation is a secure change management process.

There is, however, a fundamental difference: 21 CFR Part 11 and Annex 11 were written to ensure data integrity and regulatory compliance, not to protect against an active attacker. A system can be fully compliant with these regulations and at the same time have critical cybersecurity vulnerabilities.

GMP and Cybersecurity: Two Programs That Must Talk to Each Other

The typical problem in pharmaceutical companies is that the two programs, quality/GMP and IT/OT cybersecurity, live in separate silos. The validation team manages computerized systems according to GMP; the IT team manages information security for the infrastructure; the OT team handles industrial control systems. Cybersecurity for validated OT systems often falls in between, with no clear ownership.

The practical consequences are several:

• Paralyzed patch management: applying a patch to a validated system requires a change control procedure and potentially re-validation. This cycle, already slow under GMP, becomes almost impossible when multiplied across every security update.
• Stuck legacy systems: many pharmaceutical production systems run on operating systems that are no longer supported. Replacing them requires full re-validation, with costs and timelines that organizations postpone as long as possible.
• Vendor management: suppliers of pharmaceutical automation systems must be qualified as a "computer system supplier" under GMP, through a process that often does not include an explicit assessment of information security.

The Risk Vectors Specific to the Sector

In pharma, certain vectors deserve particular attention:

Manipulation of process data: an attacker who understands how a pharmaceutical SCADA system works might not aim to halt operations, but to silently manipulate process parameters or corrupt batch record data. The goal is to make a product non-compliant without anyone noticing until the next audit.

Networked laboratory systems: LIMS (Laboratory Information Management System) and analytical instruments with network connectivity are often overlooked in OT cybersecurity programs, yet they hold data critical to product release.

Ransomware on production systems: the pharmaceutical sector has been the target of significant ransomware attacks, with impacts on production capacity measured in weeks. For a pharmaceutical company with essential products in its portfolio, the operational cost can be enormous.

Roadmap for Integrated Compliance

The most effective approach is to build a framework that integrates GMP/regulatory requirements with cybersecurity requirements from the systems design phase onward:

1. Alignment between Computer System Validation and cybersecurity assessment: every new computerized system should include a cyber risk assessment as part of the validation process, not as a separate process.

2. Structured patch management: define a process that allows critical security patches to be applied through an accelerated path compared with standard change control, while maintaining the documentation needed for GMP compliance.

3. Network segmentation as a GMP control: the separation between GMP-critical systems and IT infrastructure is not only a security best practice; it can be argued as a GMP control to protect the integrity of computerized systems.

4. Integrated training: validation teams must understand cyber risks; security teams must understand GMP constraints. Collaboration between these functions is essential.

The pharmaceutical sector already has all the cultural tools to build robust programs: a quality mindset, rigorous documentation, structured risk management. Applying them to OT cybersecurity is the natural next step.

The MON5 Angle

In a pharmaceutical plant, every validated system is untouchable: an active scan or an agent installed on a GMP-critical SCADA risks invalidating its qualification. MON5 addresses this constraint with passive or hybrid discovery: the inventory of OT assets, from fermentation to cleanroom monitoring, is built by observing network traffic, without touching the validated systems or stopping production.

The analysis phase then correlates CVE vulnerabilities with EPSS scores and real exposure, concrete support for arguing within change control which patches deserve the accelerated path. Continuous monitoring with anomaly detection flags abnormal changes to process parameters, defending the integrity of the batch record. The starting point is an OT assessment carried out on the plant in operation.

Analysis and commentary by MON5 based on public-domain research and data from the OT/ICS sector.